Since the outbreak of the new crown epidemic, Pfizer has made a lot of revenue from the new crown vaccine. According to Pfizer’s financial report released not long ago, Pfizer’s revenue in 2021 will reach 81.3 billion US dollars, and the total revenue of new crown vaccines will reach 36.8 billion US dollars. With the approval and launch of its new crown oral antiviral drug Paxlovid, the industry believes that this may become a new growth point for Pfizer. With the successive approvals in major global markets and the key recommendations of the World Health Organization’s new crown treatment guidelines, Paxlovid has become a hot new crown treatment drug in the world today. However, according to media reports, it is unclear how many patients experienced a rebound after the entire course of treatment, but there have been many reports of a rebound in recent weeks, when symptoms of new coronary pneumonia return after completing the prescribed five-day course of treatment. Patients started to get better with Paxlovid, but when they finished the five-day course, symptoms of Will reappear, even the test becomes a darker line, or changes from negative to positive. The study found that a black line can indicate a strong positive for virus levels, usually when people are at or near their peak .
[related_posts_by_tax taxonomies=”post_tag”]
The post Does the new crown vaccine cause hepatitis?Pfizer steps up, pledges to take responsibility for social impact appeared first on Gamingsym.